LENVIMA (Eisai Australia Pty Ltd)
Product name
LENVIMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
lenvatinib mesilate
Registration type
EOI
Indication
LENVIMA (hard capsule), in combination with pembrolizumab, is now also indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).